IRONWOOD PHARMACEUTICALS, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $296.2M | $351.4M | $442.7M | $410.6M | $413.8M | $389.5M | $428.4M |
| Cost of Revenue | — | — | — | — | — | — | $3.1M | $23.9M |
| Gross Profit | — | — | — | — | — | — | $386.4M | $404.5M |
| Gross Margin | — | — | — | — | — | — | 99.2% | 94.4% |
| Operating Expenses | ||||||||
| Research & Development | — | $95.1M | $111.4M | $116.1M | $44.3M | $70.4M | $88.1M | $115.0M |
| SG&A Expense | — | $82.3M | $144.3M | $158.3M | $116.0M | $111.1M | $140.0M | $172.5M |
| Operating Income | — | $98.5M | $93.1M | $-945.4M | $250.3M | $232.3M | $142.9M | $120.1M |
| Operating Margin | — | 33.3% | 26.5% | -213.5% | 61.0% | 56.1% | 36.7% | 28.0% |
| Interest Expense | — | — | — | $21.6M | $7.6M | $31.2M | $29.5M | $36.6M |
| Pretax Income | — | $70.0M | $65.2M | $-948.1M | $252.4M | $200.7M | $108.9M | $58.9M |
| Income Tax Expense | — | $46.0M | $64.3M | $83.5M | $77.4M | $-327.8M | $2.7M | $0 |
| Net Income | — | $24.0M | $880.0K | $-1.00B | $175.1M | $528.4M | $106.2M | $21.5M |
| Net Margin | — | 8.1% | 0.3% | -226.4% | 42.6% | 127.7% | 27.3% | 5.0% |
| EPS (Basic) | — | $0.15 | $0.01 | $-6.45 | $1.13 | $3.26 | $0.67 | $0.14 |
| EPS (Diluted) | — | $0.15 | $0.01 | $-6.45 | $0.96 | $3.21 | $0.66 | $0.14 |
| Shares Outstanding (Basic) | 163.1M | 161.8M | 159.1M | 155.4M | 154.4M | 162.2M | 159.4M | 156.0M |
| Shares Outstanding (Diluted) | 163.1M | 163.0M | 160.1M | 155.4M | 186.3M | 164.4M | 160.7M | 156.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |